DrugPatentWatch Database Preview

AEMCOLO Drug Profile

« Back to Dashboard

Which patents cover Aemcolo, and what generic alternatives are available?

Aemcolo is a drug marketed by Cosmo Technologies and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-five patent family members in eighteen countries.

The generic ingredient in AEMCOLO is rifamycin. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the rifamycin profile page.

Summary for AEMCOLO

International Patents:	25
US Patents:	4
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Formulation / Manufacturing:	see details
DailyMed Link:	AEMCOLO at DailyMed

Generic Entry Opportunity Date for AEMCOLO

NDA:

210910

Dosage:

TABLET, DELAYED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for AEMCOLO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosmo Technologies	AEMCOLO	rifamycin	TABLET, DELAYED RELEASE;ORAL	210910-001	Nov 16, 2018		RX	Yes	Yes			Y
Cosmo Technologies	AEMCOLO	rifamycin	TABLET, DELAYED RELEASE;ORAL	210910-001	Nov 16, 2018		RX	Yes	Yes			Y
Cosmo Technologies	AEMCOLO	rifamycin	TABLET, DELAYED RELEASE;ORAL	210910-001	Nov 16, 2018		RX	Yes	Yes			Y
Cosmo Technologies	AEMCOLO	rifamycin	TABLET, DELAYED RELEASE;ORAL	210910-001	Nov 16, 2018		RX	Yes	Yes			Y

International Patents for AEMCOLO

Country	Document Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2006003043
Italy	MI20041295
South Korea	20080059337
South Korea	20070028441
Austria	392889
Mexico	PA06014698